|
In the second quarter of this year, Daehan Nupharm continued its growth, recording revenue of KRW 101.7 billion, an 8.93% increase compared to the same period last year. Notably, net profit surged by 155.32% YoY to KRW 5.58 billion, demonstrating strong bottom-line performance.
On the other hand, operating profit for the second quarter stood at KRW 7.3 billion, down 27.64% YoY. This decrease was primarily driven by an increase in cost-of-goods-sold (COGS) ratio, resulting from higher fixed costs associated with the operation of the new manufacturing facility, alongside rising import costs for raw and subsidiary materials amid ongoing foreign exchange rate pressures.
Despite external uncertainties—including the initial cost absorption of the new plant and persistent high exchange rates—Daehan Nupharm achieved meaningful results with substantial net profit growth. In the second half of the year, we plan to focus on cost structure optimization while expanding revenue driven by high-value-added products. |